Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements

KM Hajra, X Ji, ER Fearon - Oncogene, 1999 - nature.com
KM Hajra, X Ji, ER Fearon
Oncogene, 1999nature.com
Inactivation of the E-cadherin cell adhesion molecule is believed critical in the development
and behavior of many epithelial cancers, though mutations in the E-cadherin gene account
for inactivation in only a fraction of cases. In many breast cancer lines, E-cadherin
transcription is extinguished, but the role and significance of alterations in trans-acting
transcription factors, promoter hypermethylation, and chromatin changes remain unresolved.
To gain further insights into mechanisms underlying E-cadherin inactivation in breast …
Abstract
Inactivation of the E-cadherin cell adhesion molecule is believed critical in the development and behavior of many epithelial cancers, though mutations in the E-cadherin gene account for inactivation in only a fraction of cases. In many breast cancer lines, E-cadherin transcription is extinguished, but the role and significance of alterations in trans-acting transcription factors, promoter hypermethylation, and chromatin changes remain unresolved. To gain further insights into mechanisms underlying E-cadherin inactivation in breast cancer, we analysed somatic cell hybrids resulting from pairwise fusions between breast cancer lines with intact E-cadherin transcription (E-cad+) and lines lacking E-cadherin transcription (E-cad−). All hybrid lines failed to express E-cadherin transcripts and protein, despite the fact that E-cadherin alleles from E-cad+ lines were present in the hybrids. Elements in the proximal 108 bp of the E-cadherin promoter, when present in reporter gene constructs, were sufficient to direct strong transcription in E-cad+ breast lines, but displayed weak activity in E-cad− parental lines and hybrids. E-cadherin expression could not be restored in E-cad− lines or hybrids by treatment with a DNA demethylating agent and/or a histone deacetylase inhibitor. Our findings suggest loss of E-cadherin expression in some breast cancers may be due to dominant repression of the trans-acting pathways that regulate E-cadherin transcription.
nature.com